# Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Study · id `cardio:ct-nct07035405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07035405](<https://clinicaltrials.gov/study/NCT07035405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07035405

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 7500 participants.

## Technical summary

Registry record NCT07035405. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-04 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 7500 participants (planned count; ClinicalTrials.gov record NCT07035405, source copy `cardio:ctgov-nct07035405-2025-06-27`, retrieved 2026-10-26)
- Planned start: 2025-07-04 (anticipated) (ClinicalTrials.gov record NCT07035405, source copy `cardio:ctgov-nct07035405-2025-06-27`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07035405, source copy `cardio:ctgov-nct07035405-2025-06-27`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07035405, source copy `cardio:ctgov-nct07035405-2025-06-27`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07035405-2025-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
- Condition: Stroke
- Intervention (Drug): Colchicine 0.5 mg
- Intervention (Drug): Placebo colchicine
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Shenzhen Medical Academy of Research and Translation
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 4833a18a80b2ddbac480fa167c0be2172651c3cc746d85af28eda03e7e117e7f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
